A new method for non-hormonal female contraception using synthetic mRNA
Synthetic mRNA-mediated reversible immunocontraception
This study is exploring a new way for women to prevent pregnancy without using hormones, by using a special treatment that introduces antibodies to block sperm, making it a safe and easy option for women to manage on their own.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10695023 on NIH RePORTER |
What this research studies
This research investigates a novel approach to female contraception that does not rely on hormonal methods, which many women find unsatisfactory. It focuses on developing a reversible immunocontraceptive method that introduces antibodies into the female reproductive tract to inhibit sperm function. The researchers have identified a specific monoclonal antibody and are using a synthetic mRNA-based delivery system to ensure effective and controllable administration. The goal is to provide a safe, woman-applied contraceptive option that can be easily managed by the user.
Who could benefit from this research
Good fit: Ideal candidates for this research are women seeking non-hormonal contraceptive methods who may have experienced dissatisfaction with traditional hormonal options.
Not a fit: Patients who are not seeking contraception or those who have contraindications to immunocontraceptive methods may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide women with a safe and effective non-hormonal contraceptive option that they can control.
How similar studies have performed: While the concept of immunocontraception has been explored, this specific approach using synthetic mRNA is innovative and has not been widely tested in humans.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Santangelo, Philip J — Emory University
- Study coordinator: Santangelo, Philip J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.